2014/07/01  CFDA approved Company to conduct F351 Phase II clinical trials for the treatment of liver fibrosis, which is an important milestone in the development history of F351.

2014/06/11 Dr. Luo was invited to attend World Orphan Drug Congress Asia in Singapore, and he gave a speech on the expedited development of orphan drug in China.

© 2007~2018 shanghaigenomics.com. All rights reserved. Shanghai ICP 08017875